# A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Source: https://onco.cc/trials/nct06265727/  
OnCo record `nct06265727` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CRB-701 in advanced solid tumours, run by Corbus Pharmaceuticals Inc., now recruiting.

## Summary

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors is a phase 1/2 interventional study registered as NCT06265727 by Corbus Pharmaceuticals Inc., with 348 participants planned, started 2024-04-01 and due to reach its primary completion in 2027-01-16. Interventions recorded: CRB-701 and Anti-PD-1.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06265727
- Phase: 1/2
- Setting: A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors
- Sponsor: Corbus Pharmaceuticals Inc.
- Enrolled: 348

## Sources

- ClinicalTrials.gov NCT06265727: https://clinicaltrials.gov/study/NCT06265727

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [CRB-701](https://onco.cc/drugs/crb-701/)
- companies: [Corbus Pharmaceuticals](https://onco.cc/companies/corbus-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06265727.json